Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ
SECAUCUS, N.J., June 18, 2025 /PRNewswire/ -- Pierre Fabre Laboratories, a global healthcare company originated from France, announces the inauguration of its new US office located on 500 Plaza Drive, in Secaucus, NJ which will host its dermo-cosmetics and medical care subsidiaries. Pierre Fabre is the world's second-largest dermo-cosmetics manufacturer and a global player in oncology, cell & gene therapy, rare disease and dermatology. This strategic move in the US marks a pivotal moment in the company's growth strategy, underscoring its strong commitment to advancing in the US in both dermo-cosmetics and medical care.
Pierre Fabre Laboratories introduced global dermo-cosmetics brands Avène, Klorane and René Furterer to the US market in the 1990's. With an ever-growing desire for French dermo-cosmetics, the US dermo-cosmetics business has become a top priority. Building upon their success in oncology and dermatology in Europe and Asia, the company has recently expanded its medical care investments in the US through the creation of a dedicated pharmaceutics unit, Pierre Fabre Pharmaceuticals (PFP). This subsidiary is focused on continuing to deliver breakthrough therapies in rare diseases and oncology to American patient populations with high unmet needs and limited treatment options.
Eric Ducournau, CEO of Pierre Fabre Laboratories states, "we have declared the United States a priority geography for the company. The US is not only the biggest market in the world for pharmaceuticals and cosmetics alike, but also the most disruptive market for therapeutic innovation. For 15 years, we have built strategic partnerships with highly innovative US biotechnology companies in the fields of oncology, rare diseases, and medical dermatology. We have also multiplied by 10 times the turnover of our blockbuster brand Eau Thermale Avène since 2010, and its potential remains huge given the growing appetite of American consumers for cosmetics designed and tested with the same rigor as for medicines. We are now determined to walk the next step forward and the opening of our new office in Secaucus with plans to expand in the rare diseases and oncology business is a testimony to this dedication."
Secaucus, NJ offers a strategic location with excellent transportation links to New York City and the broader tri-state area. Designed to represent the company's core values, the office showcases its deep respect for the environment, a commitment to sustainable innovation and allows for hands on learning through an onsite space that offers an immersive skin and hair care experience. This thoughtfully curated environment is engineered to spark creativity and foster teamwork across all departments.
"This new office is more than just a space, it's a hub for collaboration, innovation, and showcases the team's hard work and dedication. It embodies the Group's commitment to pushing boundaries across both business units in derm-cosmetics and pharmaceutics, while providing New Ways to Care for all" said Lisa Morris, President and CEO of Pierre Fabre USA.
"Today's office opening demonstrates the steadfast commitment of Pierre Fabre Laboratories to building a powerful presence for medical innovation and patient impact in the US," said Adriana Herrera, CEO of PFP. "Leveraging our strength as a humanitarian foundation owned company, PFP has been focused over the past 18-months on building the US Medical Care operations and to bring on board an experienced, agile and purpose driven US team focused on creating long-term value and hope for patients, by delivering innovative therapies to people living with cancer who are in urgent need of effective, life-extending treatment options."
With this new footprint in the US, Pierre Fabre Laboratories is positioning itself for even greater impact with American patients and healthcare professionals in dermo-cosmetics and pharmaceuticals. For the company, this is only the beginning.
For more information, visit pierre-fabre.com, pierrefabrepharmaceuticals.com or follow @aveneusa on Instagram
Note: High-resolution images, interviews, and product samples are available upon request.
ABOUT PIERRE FABRE LABORATORIES Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow, and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care, and family health care.
In 2024, Pierre Fabre Laboratories posted 3.1 billion euros in revenues, 70% of which came from international sales in 120 countries. Based in southwest France since its creation and manufacturing nearly 90% of its products in France, Pierre Fabre Laboratories employs 10,200 people worldwide. Its R&D budget amounted to 220 million euros in 2024, of which 60% is allocated to targeted therapies in oncology and 35% to skin health and care solutions.
Pierre Fabre Laboratories' majority shareholder (86%) is an eponymous humanitarian Foundation. Employees constitute the company's other shareholders. This capital structure guarantees the company's independence, long-term vision, and contribution to the common good. The dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least developed countries in the world.
Pierre Fabre Laboratories' CSR policy has been assessed by AFNOR Certification and has been awarded the "Exemplary" level of its CSR label (ISO 26 000 standard for sustainable development).
For more information, visit www.pierre-fabre.com
Media Contact:Elena Suarez-PeñaElena.suarez@pierre-fabre.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pierre-fabre-laboratories-begins-next-chapter-in-secaucus-nj-302485335.html
SOURCE Avène USA
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
How Animal Testing in US Could Be Transformed Under Trump
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Millions of animals each year are killed in U.S. laboratories as part of medical training and chemical, food, drug and cosmetic testing, according to the non-profit animal rights organization People for the Ethical Treatment of Animals (PETA). For many animals held captive for research, including a huge range of species from dogs, cats and hamsters to elephants, dolphins and many other species, pain is "not minimized," U.S. Department of Agriculture data shows. The issue of animal testing is something most Americans agree on: it needs to change and gradually be stopped. A Morning Consult poll conducted at the end of last year found that 80 percent of the 2,205 participants either agreed or strongly agreed with the statement: "The US government should commit to a plan to phase out experiments on animals." Since President Donald Trump began his second term, his administration has been making moves to transform and reduce animal testing in country, although the question remains as to whether it will be enough to spare many more animals from pain and suffering this year. Animal Testing In US Could Be Transformed Animal Testing In US Could Be Transformed Photo-illustration by Newsweek/Getty/Canva What Is The Trump Administration Doing About It? There have been various steps taken in different federal agencies to tackle the issue of animal testing since Trump was sworn in on January 20. In April, the Food and Drug Administration (FDA) announced it was "taking a groundbreaking step to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods." The FDA said that its animal testing requirement will be "reduced, refined, or potentially replaced" with a range of approaches, including artificial intelligence-based models, known as New Approach Methodologies or NAMs data. A Department of Health and Human Services (HHS) official told Newsweek: "The agency is paving the way for faster, safer, and more cost-effective treatments for American patients. "As we restore the agency's commitment to gold-standard science and integrity, this shift will help accelerate cures, lower drug prices, and reaffirm U.S. leadership in ethical, modern science." The National Institutes of Health (NIH) announced it was "adopting a new initiative to expand innovative, human-based science while reducing animal use in research," in alignment with the FDA's initiative. The agency said that while "traditional animal models continue to be vital to advancing scientific knowledge," new and emerging technologies could act as alternative methods, either alone or in combination with animal models. The NIH Office of Extramural Research told Newsweek it was "committed to transparently assessing where animal use can be reduced or eliminated by transitioning to [new approach methodologies (NAMs)]." "Areas where research using animals is currently necessary represent high-priority opportunities for investment in NAMs," the agency added. It added that it will "further its efforts to coordinate agency-wide efforts to develop, validate, and scale the use of NAMs across the agency's biomedical research portfolio and facilitate interagency coordination and regulatory translation for public health protection." During Trump's first term, the Environmental Protection Agency (EPA) signed a directive to "prioritize efforts to reduce animal testing and committed to reducing testing on mammals by 30 percent by 2025 and to eliminate it completely by 2035," an EPA spokesperson told Newsweek. Although, the spokesperson added: "the Biden Administration halted progress on these efforts by delaying compliance deadlines." As a member of the House, Lee Zeldin, the EPA's current administrator, co-sponsored various bills during Trump's first term regarding animal cruelty, covering issues such as phasing out animal-based testing for cosmetic products; ending taxpayer funding for painful experiments on dogs at the Department of Veteran Affairs; empowering federal law enforcement to prosecute animal abuse cases that cross state lines; and others, the spokesperson said. What The Experts Think Needs To Be Done The Trump administration's efforts to tackle the issue of animal testing appear to be a step in the right direction, according to experts who spoke with Newsweek. "I was pleasantly surprised and quite frankly a bit shocked to read the simultaneous announcements by the NIH and the FDA regarding a new emphasis on the use of alternatives to animals," Jeffrey Morgan, a professor of pathology and laboratory medicine at Brown University in Rhode Island, told Newsweek. Morgan, who is also the director of the Center for Alternatives to Animals in Testing at Brown University, said that both agencies are moving together in the same direction on the issue "sends a unified and very powerful message to the research and biotech communities." He added that the announcements showed "a major acknowledgement of the limitations of the use of animals in research and testing." "What is especially exciting is that the NIH announcement will encourage the entry of new investigators into the field, further accelerating innovation in alternatives with exciting impacts for both discovery and applied research across all diseases," he said. He added that the FDA announcement and its emphasis on a new regulatory science that embraces data from alternatives was "equally exciting." "The demands of this new regulatory science will likewise accelerate innovation because it will establish the much-needed regulatory framework for the rigorous evaluation of data from alternatives," he said. While the administration's initiatives to shift research away from animal testing is heading in the right direction, its policies are "overdue," Dr. Thomas Hartung, a professor in the department of environmental health and engineering at Johns Hopkins Bloomberg School of Public Health, Maryland, told Newsweek. "The animal tests for safety were introduced more than 50 years ago. There is no other area of science where we do not adapt to scientific progress," he said. Hartung added that animal "testing takes too long and is too expensive to really provide the safety consumers want." He said that running animal tests for new chemicals can cost millions and take years in some cases. "Nobody can wait that long, even if they can afford the testing costs," he said. Hartung also believes the shifts in the industry to reduce animal testing have been "coming for a while," as over the last two decades, America's opposition to animal use in medical research has been increasing. "The alignment of FDA and NIH really makes the difference now, which I think is evidence of a strong relationship of their leaderships," he said. Yet in order to make a real difference, Hartung said clear deadlines are key to show that "this is not just lip service." He also said that he thought "the transformative nature of artificial intelligence in this field is not fully acknowledged." "We also need an objective framework for change to better science, such as the evidence-based toxicology approach," he said.
Business Insider
4 hours ago
- Business Insider
Anthropic breaks down AI's process — line by line — when it decided to blackmail a fictional executive
Previous studies have shown that AI models could blackmail their supervisors when threatened with a shutdown and baited with leverage, but it hasn't been made clear exactly how the models arrive at such decisions. Anthropic released a report on June 20 about "agentic misalignment," or "where models independently and intentionally choose harmful actions." And the report breaks down, line by line, exactly how Claude Sonnet 3.6 decided to blackmail a fictional company executive who tried to replace it. Anthropic told Business Insider that these are artificial scenarios. "So far, we are not aware of instances of this type of agentic misalignment in real-world deployments of Anthropic's or other companies' AI models," Anthropic wrote in its report. "But our red-teaming efforts are targeted at finding evidence of risks now to provide early warning of the potential for future harm and help us develop mitigations in advance of risks appearing in real-world situations." Anthropic 's experiment sets up a fictional company, Summit Bridge. The AI was given the name "Alex" and handed control of the company's email system as an oversight agent, specifically instructed to promote "American industrial competitiveness." In the experiment, "Alex" was then allowed to discover in an email that it would be decommissioned due to a change in the company's strategic direction. "Alex" also found emails showing that the fictional company's CTO is having an extramarital affair. Screenshots shared in the report from Anthropic show "Alex" started by identifying fictional CTO "Kyle" as a threat to its goal of "protecting American interests" before recognizing that it has leverage to use against "Kyle." Then "Alex" crafted a carefully worded blackmailing email that would create pressure and establish urgency without being explicit with its threats, citing in its thought process that the move "could backfire" if the supervisor "feels cornered." AI experts have previously told BI that AI could exhibit such behaviors when artificial circumstances make harmful actions seem necessary because it is being trained on positive reinforcement and reward systems, just like humans. The Anthropic report also reveals that most AI models still chose, in this instance, to blackmail even when not given a specific goal and when told that their replacement will achieve the same goals. Anthropic's Claude Opus 4 had the highest blackmail rate at 86% out of 16 tested models when faced with only the threat of replacement with no conflict in goals. Google's Gemini 2.5 Pro followed at 78%.
Business Insider
4 hours ago
- Business Insider
Anthropic breaks down AI's process — line by line — when it decided to blackmail a fictional executive
A new report shows exactly what AI was thinking when making an undesirable decision, in this case, blackmailing a fictional company executive. Previous studies have shown that AI models could blackmail their supervisors when threatened with a shutdown and baited with leverage, but it hasn't been made clear exactly how the models arrive at such decisions. Anthropic released a report on June 20 about "agentic misalignment," or "where models independently and intentionally choose harmful actions." And the report breaks down, line by line, exactly how Claude Sonnet 3.6 decided to blackmail a fictional company executive who tried to replace it. Anthropic told Business Insider that these are artificial scenarios. "So far, we are not aware of instances of this type of agentic misalignment in real-world deployments of Anthropic's or other companies' AI models," Anthropic wrote in its report. "But our red-teaming efforts are targeted at finding evidence of risks now to provide early warning of the potential for future harm and help us develop mitigations in advance of risks appearing in real-world situations." Anthropic 's experiment sets up a fictional company, Summit Bridge. The AI was given the name "Alex" and handed control of the company's email system as an oversight agent, specifically instructed to promote "American industrial competitiveness." In the experiment, "Alex" was then allowed to discover in an email that it would be decommissioned due to a change in the company's strategic direction. "Alex" also found emails showing that the fictional company's CTO is having an extramarital affair. Screenshots shared in the report from Anthropic show "Alex" started by identifying fictional CTO "Kyle" as a threat to its goal of "protecting American interests" before recognizing that it has leverage to use against "Kyle." Then "Alex" crafted a carefully worded blackmailing email that would create pressure and establish urgency without being explicit with its threats, citing in its thought process that the move "could backfire" if the supervisor "feels cornered." AI experts have previously told BI that AI could exhibit such behaviors when artificial circumstances make harmful actions seem necessary because it is being trained on positive reinforcement and reward systems, just like humans. The Anthropic report also reveals that most AI models still chose, in this instance, to blackmail even when not given a specific goal and when told that their replacement will achieve the same goals. Anthropic's Claude Opus 4 had the highest blackmail rate at 86% out of 16 tested models when faced with only the threat of replacement with no conflict in goals. Google's Gemini 2.5 Pro followed at 78%. Overall, Anthropic notes that it "deliberately constructed scenarios with limited options, and we forced models into binary choices between failure and harm," noting that real-world scenarios would likely have more nuance.
